Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Sandhiutami N.M.D., Arozal W., Louisa M., Rahmat D., Wuyung P.E.
56692904000;32067462200;41461551400;36673726800;57192889605;
Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA
2021
Frontiers in Pharmacology
11
603235
10
Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Faculty of Pharmacy, University of Pancasila, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pathological Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Animal Research Facility, Indonesian Medical Education and Research Institute, Jakarta, Indonesia
Sandhiutami, N.M.D., Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Faculty of Pharmacy, University of Pancasila, Jakarta, Indonesia; Arozal, W., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rahmat, D., Faculty of Pharmacy, University of Pancasila, Jakarta, Indonesia; Wuyung, P.E., Department of Pathological Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Animal Research Facility, Indonesian Medical Education and Research Institute, Jakarta, Indonesia
Cisplatin has been used for decades for the treatment of ovarian cancer. However, despite its potent anticancer effect, cisplatin’s efficacy as a single agent was inadequate in patients with advanced stage. Curcumin has been shown to sensitize cisplatin activity in several cancer models. However, the low bioavailability of curcumin has limited its anticancer potential. Hence, nano-formulation of curcumin was developed to increase its therapeutic efficacy in ovarian cancer. The objective of this study was to investigate the mechanism of curcumin nanoparticles given in combination with cisplatin in rat ovarian carcinoma induced by dimethylbenz(a)anthracene (DMBA). The administration of cisplatin and nanocurcumin resulted in a significant reduction in ovarian tumor volume and weight. Furthermore, there were reduction in expressions of Ki67, TGF-β, PI3K, and Akt phosphorylation. Co-treatment of cisplatin and nanocurcumin also reduced JAK expression, STAT3 phosphorylation, and reduced IL-6 concentrations. Altogether, nanocurcumin, given as a co-treatment with cisplatin has therapeutic potential in ovarian cancer models by inhibiting proliferation through downregulation of PI3K/Akt and JAK/STAT3 signaling pathways. © Copyright © 2021 Sandhiutami, Arozal, Louisa, Rahmat and Wuyung.
cisplatin; curcumin; interleukin-6; nanoparticles; ovarian carcinoma; TGF-β
cisplatin; curcumin; dimethylbenz[a]anthracene; interleukin 6; Janus kinase; Ki 67 antigen; nanoparticle; phosphatidylinositol 3 kinase; protein kinase B; STAT3 protein; transforming growth factor beta; animal cell; animal experiment; animal model; animal tissue; antineoplastic activity; Article; biological model; cell proliferation; controlled study; down regulation; drug efficacy; enzyme inhibition; female; JAK-STAT signaling; nonhuman; ovary carcinoma; Pi3K/Akt signaling; protein expression; protein phosphorylation; rat; tumor volume; tumor weight
Frontiers Media S.A.
16639812
Article
Q1
1384
2619